Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Yorston, Graeme
and
Pinney, Alison
1997.
Use of high dose antipsychotic medication.
Psychiatric Bulletin,
Vol. 21,
Issue. 9,
p.
566.
Newton, K. L.
Murthy, R.
and
Qureshi, J.
1997.
Antipsychotic prescribing in light of the consensus statement of the College.
Psychiatric Bulletin,
Vol. 21,
Issue. 7,
p.
408.
Taylor, John R.
and
Cookson, Ian B.
1997.
Audit of out-patients on ‘higher dose’ antipsychotics.
Psychiatric Bulletin,
Vol. 21,
Issue. 7,
p.
445.
Barber, Joan M.
Connaughton, Jennifer
and
Wright, Morag
1998.
Monitoring patients on high-dose antipsychotics.
Psychiatric Bulletin,
Vol. 22,
Issue. 11,
p.
671.
Milton, John
Lawton, John
Smith, Mark
and
Buckley, Ann
1998.
Hidden high-dose antipsychotic prescribing: effects of p.r.n. doses.
Psychiatric Bulletin,
Vol. 22,
Issue. 11,
p.
675.
Spence, Sean A.
Hirsch, Steven R.
Brooks, David J.
and
Grasby, Paul M.
1998.
Prefrontal cortex activity in people with schizophrenia and control subjects.
British Journal of Psychiatry,
Vol. 172,
Issue. 4,
p.
316.
Tyson, Philip J.
Mortimer, Ann M.
and
Wheeler, Jason A
1999.
High-dose antipsychotic treatment in clinical practice.
Psychiatric Bulletin,
Vol. 23,
Issue. 11,
p.
661.
Spence, Sean A.
Liddle, Peter F.
Stefan, Martin D.
Hellewell, Jonathan S. E.
Sharma, Tonmoy
Friston, Karl J.
Hirsch, Steven R.
Frith, Christopher D.
Murray, Robin M.
Deakin, J. F. William
and
Grasby, Paul M.
2000.
Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk.
British Journal of Psychiatry,
Vol. 176,
Issue. 1,
p.
52.
Yorston, Graeme
and
Pinney, Alison
2000.
Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics.
Psychiatric Bulletin,
Vol. 24,
Issue. 4,
p.
130.
Shah, Rashmi R.
2002.
Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity.
Fundamental & Clinical Pharmacology,
Vol. 16,
Issue. 2,
p.
147.
Shah, Rashmi
2002.
Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern.
Dialogues in Clinical Neuroscience,
Vol. 4,
Issue. 4,
p.
449.
Harrington, Maria
Lelliott, Paul
Paton, Carol
Okocha, Chike
Duffett, Richard
and
Sensky, Tom
2002.
The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK.
Psychiatric Bulletin,
Vol. 26,
Issue. 11,
p.
414.
Shah, Rashmi R.
2002.
The significance of QT interval in drug development.
British Journal of Clinical Pharmacology,
Vol. 54,
Issue. 2,
p.
188.
Shah, Rashmi R.
2002.
Drug‐induced prolongation of the QT interval: why the regulatory concern?.
Fundamental & Clinical Pharmacology,
Vol. 16,
Issue. 2,
p.
119.
Shah, Rashmi R
2004.
Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes.
Drug Safety,
Vol. 27,
Issue. 3,
p.
145.
Shah, Rashmi
2004.
Drug‐induced QT interval prolongation: regulatory perspectives and drug development.
Annals of Medicine,
Vol. 36,
Issue. sup1,
p.
47.
Shah, Rashmi R
2005.
Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules.
Expert Opinion on Drug Safety,
Vol. 4,
Issue. 1,
p.
103.
Shah, Rashmi R
2005.
Pharmacogenetics in drug regulation: promise, potential and pitfalls.
Philosophical Transactions of the Royal Society B: Biological Sciences,
Vol. 360,
Issue. 1460,
p.
1617.
Shah, Rashmi R
2006.
Can Pharmacogenetics Help Rescue Drugs Withdrawn from the Market?.
Pharmacogenomics,
Vol. 7,
Issue. 6,
p.
889.
Lin, Yeong‐Liang
Wu, Ya‐Chi
and
Tsai, Guei‐Feng
2009.
Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone—A claims database approach.
Pharmacoepidemiology and Drug Safety,
Vol. 18,
Issue. 9,
p.
842.
eLetters
No eLetters have been published for this article.